Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (353)	12/18/1998 5:10:00 PM
From: JAMES BORECKI	Read Replies (2) \| Respond to of 1321

Good movement on Good news. I've been waiting almost 3 years. Any other old timers out there. JimB ------------------------- December 18, 1998 14:28 QLT shrs up on positive report on partner Jump to first matched term TORONTO, Dec 18 (Reuters) - Shares in QLT PhotoTherapeutics Inc. rose to a new 52-week high after a London broker issued a positive report on Novartis AG , its partner in developing a drug to treat a leading cause of blindness. According to QLT and analysts, the climb in the stock was probably attributable to a bullish report from Warburg Dillon Read about Novartis which also discussed QLT and the drug Verteporfin, used to treat Age-related Macular Degeneration (AMD). "There was a very positive report that was written about Novartis a couple of days ago by Warburg Dillon Read and they talked about QLT a lot. That's the only thing that's really happened of late," said a QLT spokeswoman. QLT will release results from phase III trials of Verteporfin in the first quarter of 1999. "They put out a report talking about Novartis, talking about BPD, QLT's drug, as an US$800 million drug. That's a good number," said Duncan Stewart, fund manager at Tera Capital. The Warburg Dillion Read analyst was unavailable for comment. QLT surged to a 52-week high of C$29.55 on the Toronto Stock Exchange before pulling back slightly to trade C$3, or 11.5 percent, higher at C$29. On Nasdaq, the stock climed 1-15/16 to 18-13/16. "The company is expected to come out with very favorable data from one of their clinical trials," said Michael Jams, analyst at Levesque Beaubien Geoffrion.